Topline data were announced from two phase 3 trials evaluating oveporexton in patients with narcolepsy type 1.

Ireland-based Alkermes has announced positive topline results from the randomized double-blind treatment period of the ...

Alkermes ALKS announced positive top-line data from the phase II Vibrance-1 study, which evaluated its novel, investigational ...

A race to develop a new class of drugs could transform treatment for patients with narcolepsy — as well as for patients with ...

Alkermes stock skidded Monday on the back of mixed results for its experimental narcolepsy treatment, an orexin agonist.

Alkermes' alixorexton met key endpoints in a Phase 2 trial for narcolepsy type 1, showing strong efficacy and tolerability ...

Part of a class of therapies that boost “orexin” proteins, the drug just scored positive results in a Phase 2 trial. Analysts ...

Alkermes outlined plans to move its NT1 drug candidate, alixorexton, into phase 3 after posting results from the midstage ...

Alkermes’ investigational drug helped people with a type of narcolepsy stay awake during the day in a mid-stage trial.

Long term use of once-nightly sodium oxybate is well-tolerated among patients with narcolepsy type 1 or 2 with primarily mild adverse reactions.

Narcolepsy in dogs is pretty rare, but it does happen, especially in certain breeds. It’s a neurological disorder that ...

Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK) shares rose 3.5% following the announcement of encouraging Phase 3 trial results for its investigational narcolepsy treatment, oveporexton. The Japanese ...